-
Cyberonics' New Kit for VNS - Analyst Blog
Thursday, February 3, 2011 - 12:05pm | 526Recently Cyberonics Inc. (CYBX), a leading neuromodulation company, has received approval from the US Food and Drug Administration (FDA) for AspireHC (High Capacity), a new and improved generator to be used in vagus nerve stimulation (VNS) therapy. Cyberonics expects the AspireHC generator,...
-
Cyberonics' New Kit for VNS - Analyst Blog
Thursday, February 3, 2011 - 11:30am | 526Recently Cyberonics Inc. (CYBX), a leading neuromodulation company, has received approval from the US Food and Drug Administration (FDA) for AspireHC (High Capacity), a new and improved generator to be used in vagus nerve stimulation (VNS) therapy. Cyberonics expects the AspireHC generator,...
-
Unconfirmed Rumors Circulate that Delcath Systems Inc. (DCTH) will get an FDA fast-track approval for stage 3 liver cancer treatment
Thursday, February 3, 2011 - 11:19am | 32Unconfirmed Rumors Circulate that Delcath Systems Inc. (DCTH) will get an FDA fast-track approval for stage 3 liver cancer treatment..Stock would trade to Mid 20s..
-
Morning Market Movers (FRG, HNSN, DSCI, SGI)
Thursday, February 3, 2011 - 11:04am | 148Fronteer Gold Inc (AMEX: FRG) jumped 39.52% to $14.51 at 10:00 am. Newmont Mining Corp (NYSE: NEM) announced its plans to buy all of the outstanding common shares of FRG for C$2.3 billion by way of a Plan of Arrangement. Hansen Medical Inc (NASDAQ: HNSN) shares advanced 36.71% to $2.16. Philips...
-
Company News for February 03, 2011 - Corporate Summary
Thursday, February 3, 2011 - 11:01am | 591• Avery Dennison (NYSE:AVY) reported Q4 EPS of $0.98, missing the Zacks Consensus of $0.97 per share by a penny. Revenues for the quarter rose 8% year-over-year to $1.64 billion, ahead of the Zacks Consensus Estimate of $1.60 billion • Hospira (NYSE:HSP) reported Q4 EPS of $0.77, lower than the...
-
Earnings Scorecard: St. Jude - Analyst Blog
Thursday, February 3, 2011 - 11:01am | 1311Medical devices major St. Jude Medical (STJ) posted better-than-expected fourth quarter fiscal 2010 results in a still challenging operating backdrop with adjusted earnings of 75 cents beating the Zacks Consensus Estimates by a penny while exceeding the year-ago earnings of 64 cents. Fourth...
-
Earnings Scorecard: St. Jude - Analyst Blog
Thursday, February 3, 2011 - 10:30am | 1311Medical devices major St. Jude Medical (STJ) posted better-than-expected fourth quarter fiscal 2010 results in a still challenging operating backdrop with adjusted earnings of 75 cents beating the Zacks Consensus Estimates by a penny while exceeding the year-ago earnings of 64 cents. Fourth...
-
Company News for February 03, 2011 - Corporate Summary
Thursday, February 3, 2011 - 10:15am | 591• Avery Dennison (NYSE:AVY) reported Q4 EPS of $0.98, missing the Zacks Consensus of $0.97 per share by a penny. Revenues for the quarter rose 8% year-over-year to $1.64 billion, ahead of the Zacks Consensus Estimate of $1.60 billion • Hospira (NYSE:HSP) reported Q4 EPS of $0.77, lower than the...
-
Active Screen: CANSLIM for February 2nd
Thursday, February 3, 2011 - 9:54am | 1165Our CANSLIM screen from lat week introduced a new stock, Free McMoran (FCX) at the expense of Netflix (NFLX). It joined the other stocks, Apple (AAPL), Baidu (BIDU), Research in Motion (RIMM), Celgene Corporation (CELG), Cognizant Technology Solutions (CTSH), Southwestern Energy (SWN), Intuitive...
-
Piper Jaffray Reiterates Clinical Data Overweight, $31 PT (CLDA)
Thursday, February 3, 2011 - 9:38am | 130Piper Jaffray reiterated its Clinical Data (NASDAQ: CLDA) Overweight rating and $31 price target in a research report published today. In the report, Piper Jaffray states, "Clinical Data's Chairman recently commented in an interview with Reuters that the company has a brief window while it plans a...
-
Benzinga's Top Downgrades (LUV, BSX, APC, KBH)
Thursday, February 3, 2011 - 9:29am | 139Southwest Airlines Company (NYSE: LUV) was downgraded by Argus from "buy" to "hold." LUV's shares closed at $11.57 yesterday. Southwest Airlines' PEG ratio is 2.30. Boston Scientific Corporation (NYSE: BSX) was downgraded by BMO Capital from "outperform" to "market perform." BSX's stock closed at $...
-
Citigroup Upgrades Hospira To Hold, PT To $52
Thursday, February 3, 2011 - 9:20am | 26Citigroup has upgraded Hospira (NYSE: HSP) from Sell to Hold and has lowered the price target from $53 to $52.
-
Goldman Sachs Lowers PT on Hospira to $59 (HSP)
Thursday, February 3, 2011 - 9:06am | 114Goldman Sachs is out with its report on Hospira (NYSE: HSP), lowering its price target from $65 to $59. In a note to clients, Goldman Sachs writes, "Following Hospira's 4Q2010, we lower EPS forecasts for 2011-2014 to $3.93/$4.53/$5.06/$5.52 from $4.32/$5.01/$5.60/$6.07 on the basis of lower...
-
CONMED Misses Revenue Estimates (CNMD)
Thursday, February 3, 2011 - 8:27am | 171Utica, New York-based CONMED Corporation (Nasdaq: CNMD) on Thursday morning released financial results that met Wall Street earnings expectations, while missing revenue estimates. CONMED Corporation reported that its 4th quarter net income rose to $7.0 million, or 24 cents per share, up from $5.0...
-
Deutsche Bank Maintains Hold On Boston Scientific (BSX)
Thursday, February 3, 2011 - 8:24am | 146Deutsche Bank is maintaining its Hold rating and $7.40 price target on shares of Boston Scientific Corporation (NYSE: BSX) after the company reported earnings. In a note to clients, Deutsche Bank writes, "BSX has undesirable weightings in declining and/or mature markets due to pricing and/or volume...